LH Differentiation in Hypogonadism Classification

Diagnostic Classification Based on LH Levels

The European Association of Urology recommends that LH levels are the critical laboratory marker that distinguishes primary (hypergonadotropic) hypogonadism from secondary (hypogonadotropic) hypogonadism, and this distinction fundamentally determines treatment strategy—particularly whether fertility preservation is possible 1, 2
Elevated LH and FSH levels occur due to testicular failure, as the pituitary attempts to compensate for inadequate testosterone production, which is a characteristic of primary hypogonadism 1, 2
Low or inappropriately normal LH and FSH levels despite low testosterone, indicating hypothalamic-pituitary dysfunction, is a characteristic of secondary hypogonadism 1, 2
The European Urology Association states that patients with secondary hypogonadism can potentially achieve both normal testosterone levels AND fertility with gonadotropin therapy (hCG and FSH) 3

The Endocrine Society recommends confirming hypogonadism with two morning total testosterone measurements below normal range on separate days, and presence of specific symptoms: reduced libido, erectile dysfunction, decreased spontaneous erections 4, 3, 5, 6
Measuring LH and FSH levels is crucial in determining the type of hypogonadism, with elevated LH/FSH indicating primary hypogonadism, and low or inappropriately normal LH/FSH indicating secondary hypogonadism 1, 3

For secondary hypogonadism seeking fertility, combined hCG and FSH therapy provides optimal outcomes, according to the European Urology Association 3, 4
For primary hypogonadism, testosterone replacement is the only option, and sperm banking should be offered before treatment if any residual spermatogenesis exists, as recommended by the European Association of Urology 1, 3
For functional hypogonadism with low-normal LH, addressing underlying conditions first, such as weight loss and metabolic disease management, can normalize both testosterone and LH levels, and consider combining lifestyle changes with testosterone therapy for symptomatic patients, as suggested by the European Urology Association 4, 3